Literature DB >> 29070968

Predictors of Mortality in Veterans with Multiple Sclerosis in an Outpatient Clinic Setting.

Meheroz H Rabadi, Christopher E Aston.   

Abstract

BACKGROUND: Examining factors that increase risk of death in veterans with multiple sclerosis (MS) may help reduce MS-related mortality. We sought to determine predictors of mortality in veterans with MS attending an outpatient clinic.
METHODS: Review of electronic medical records of 226 veterans with MS regularly followed up from January 1, 2000, through December 31, 2014.
RESULTS: Mortality at the end of the 15-year study period was 14%. Patients with MS died prematurely, with a standardized mortality rate of 1.35 relative to the general (Oklahoma) population. The main causes of death documented were MS disease itself (57% of cases), infection (43%), and cancer and respiratory failure (18% each). Cox regression analysis using the whole cohort showed that progressive MS type; older age at entry into the study; presence of sensory, cerebellar, or motor (weakness and/or ataxia) concerns on presentation; more disability on presentation; higher body-mass index; being diabetic; never received disease-modifying therapy; and presence of pressure ulcers or neurogenic bladder were significant predictors of higher mortality.
CONCLUSIONS: Initial presentation by MS type (progressive MS), higher level of disability, and associated motor, sensory, and cerebellar concerns are significant predictors of MS-related mortality. The main causes of death were MS disease itself, infection, respiratory disease, and cancer. More attention should be given to preventive strategies that delay mortality, such as yearly immunization and aggressively treating MS-related complications and diabetes mellitus.

Entities:  

Year:  2017        PMID: 29070968      PMCID: PMC5649351          DOI: 10.7224/1537-2073.2016-067

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  27 in total

1.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

2.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

3.  Prevalence estimates for MS in the United States and evidence of an increasing trend for women.

Authors:  Curtis W Noonan; Steven J Kathman; Mary C White
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

4.  A prospective study of the incidence, prevalence and mortality of multiple sclerosis in Leeds.

Authors:  Helen L Ford; Edwina Gerry; Michael Johnson; Rhys Williams
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

5.  Body size and risk of MS in two cohorts of US women.

Authors:  Kassandra L Munger; Tanuja Chitnis; Alberto Ascherio
Journal:  Neurology       Date:  2009-11-10       Impact factor: 9.910

6.  Prevalence and costs of chronic conditions in the VA health care system.

Authors:  Wei Yu; Arliene Ravelo; Todd H Wagner; Ciaran S Phibbs; Aman Bhandari; Shuo Chen; Paul G Barnett
Journal:  Med Care Res Rev       Date:  2003-09       Impact factor: 3.929

7.  Multiple sclerosis outcome and morbi-mortality of a Brazilian cohort patients.

Authors:  Soniza Vieira Alves-Leon; Fabíola Rachid Malfetano; Maria Lucia Veluttini Pimentel; Claudio Luiz Duque Estrada; Valéria Coelho Santa Rita Pereira; Assuncíon Martinez Liem; Sérgio Augusto Pereira Novis
Journal:  Arq Neuropsiquiatr       Date:  2008-09       Impact factor: 1.420

8.  Long-term prognosis of multiple sclerosis in Australia.

Authors:  J G McLeod; M H Barnett; P Macaskill; D B Williams
Journal:  J Neurol Sci       Date:  2007-03-21       Impact factor: 3.181

9.  Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway.

Authors:  N Grytten Torkildsen; S A Lie; J H Aarseth; H Nyland; K M Myhr
Journal:  Mult Scler       Date:  2008-07-16       Impact factor: 6.312

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  2 in total

1.  Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS.

Authors:  Edward J Fox; Fred D Lublin; Jerry S Wolinsky; Jeffrey A Cohen; Ian M Williams; Xiangyi Meng; Marina Ziehn; Scott Kolodny; Bruce A C Cree
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-09-11

2.  The prevalence of antibiotic-resistant and multidrug-resistant bacteria in urine cultures from inpatients with spinal cord injuries and disorders: an 8-year, single-center study.

Authors:  Vladimír Šámal; Vít Paldus; Daniela Fáčková; Jan Mečl; Jaroslav Šrám
Journal:  BMC Infect Dis       Date:  2022-03-09       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.